Skip to main content
Erschienen in: Urolithiasis 6/2003

01.02.2003 | Original Paper

Botulinum toxin type A may improve bladder function in a rat chemical cystitis model

verfasst von: Selahittin Çayan, Banu Coşkun, Murat Bozlu, Deniz Acar, Erdem Akbay, Ercüment Ulusoy

Erschienen in: Urolithiasis | Ausgabe 6/2003

Einloggen, um Zugang zu erhalten

Abstract

The purpose of this study was to investigate the effect of botulinum toxin type A on bladder function and histology in a rat chemical cystitis model. The study included 41 female Sprague-Dawley rats with chemical cystitis induced by intravesical instillation of hydrochloric acid. The acid instillation was repeated monthly to maintain chronic inflammation. The treatment group (n=21) received 2–3 units of botulinum toxin type A injected into the bladder detrusor at the 3, 6, 9 and 12 o'clock positions, and the control group (n=20) underwent saline injection into the bladder detrusor at the same positions. Urodynamic studies were performed in all rats before the treatment and at death. The rats were killed at 1 week, 2 weeks, 1 month and 2 months after treatment. The bladders were removed and examined histologically for mast cells and inflammatory changes. The cystometric findings showed that, at the beginning and end of the experiment, the increases in the maximum bladder capacity and compliance were significantly higher in the treatment group than in the control group (P=0.000 and P=0.025, respectively). The histological studies revealed similar mast cell counts and leukocyte infiltration for the treatment and control groups. In conclusion, in this rat chemical cystitis model, botulinum toxin type A injected into the bladder detrusor led to a functional improvement. Thus, botulinum toxin type A injection may be an alternative, minimally invasive choice to other surgical treatment options in the treatment of a chronic inflammatory condition to improve deteriorated bladder function.
Literatur
1.
Zurück zum Zitat Anonymous (1991) Clinical use of botulinum toxin. National Institutes of Health Consensus Development Conference Statement, Nov 12–14, 1990. Arch Neurol 48: 1294PubMed Anonymous (1991) Clinical use of botulinum toxin. National Institutes of Health Consensus Development Conference Statement, Nov 12–14, 1990. Arch Neurol 48: 1294PubMed
2.
Zurück zum Zitat Awad SA, Al-Zahrani HM, Gajewski JB, Bourque-Kehoe AA (1998) Long-term results and complications of augmentation ileocystoplasty for idiopathic urge incontinence in women. Br J Urol 81: 569CrossRefPubMed Awad SA, Al-Zahrani HM, Gajewski JB, Bourque-Kehoe AA (1998) Long-term results and complications of augmentation ileocystoplasty for idiopathic urge incontinence in women. Br J Urol 81: 569CrossRefPubMed
3.
Zurück zum Zitat Barbalias GA, Liatsikos EN, Athanasopoulos A, Nikiforidis G (2000) Interstitial cystitis: bladder training with intravesical oxybutynin. J Urol 163: 1818PubMed Barbalias GA, Liatsikos EN, Athanasopoulos A, Nikiforidis G (2000) Interstitial cystitis: bladder training with intravesical oxybutynin. J Urol 163: 1818PubMed
4.
Zurück zum Zitat Bjorling DE, Jerde TJ, Zine MJ, Busser BW, Saban MR, Saban R (1999) Mast cells mediate the severity of experimental cystitis in mice. J Urol 162: 231PubMed Bjorling DE, Jerde TJ, Zine MJ, Busser BW, Saban MR, Saban R (1999) Mast cells mediate the severity of experimental cystitis in mice. J Urol 162: 231PubMed
5.
Zurück zum Zitat Borodic GE, Joseph M, Fay L, Cozzolino D, Ferrante RJ (1990) Botulinum A toxin for the treatment of spasmodic torticollis: dysphagia and regional toxin spread. Head Neck 12: 392PubMed Borodic GE, Joseph M, Fay L, Cozzolino D, Ferrante RJ (1990) Botulinum A toxin for the treatment of spasmodic torticollis: dysphagia and regional toxin spread. Head Neck 12: 392PubMed
6.
Zurück zum Zitat Çayan S, Chermansky C, Schlote N, Sekido N, Nunes L, Dahiya R, Tanagho EA (2002) The bladder acellular matrix graft in a rat chemical cystitis model: functional and histologic evaluation. J Urol 168: 798PubMed Çayan S, Chermansky C, Schlote N, Sekido N, Nunes L, Dahiya R, Tanagho EA (2002) The bladder acellular matrix graft in a rat chemical cystitis model: functional and histologic evaluation. J Urol 168: 798PubMed
7.
Zurück zum Zitat Elgebaly SA, Allam ME, Walzak MPJr, Oselinsky D, Gillies C, Yamase H (1992) Urinary neutrophil chemotactic factors in interstitial cystitis patients and a rabbit model of bladder inflammation. J Urol 147: 1382PubMed Elgebaly SA, Allam ME, Walzak MPJr, Oselinsky D, Gillies C, Yamase H (1992) Urinary neutrophil chemotactic factors in interstitial cystitis patients and a rabbit model of bladder inflammation. J Urol 147: 1382PubMed
8.
Zurück zum Zitat Fowler CJ (2000) Intravesical treatment of overactive bladder. Urology 55 [Suppl 5A]: 60 Fowler CJ (2000) Intravesical treatment of overactive bladder. Urology 55 [Suppl 5A]: 60
9.
Zurück zum Zitat Gillenwater JY, Wein AJ (1988) Summary of the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases workshop on interstitial cystitis. J Urol 140: 203PubMed Gillenwater JY, Wein AJ (1988) Summary of the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases workshop on interstitial cystitis. J Urol 140: 203PubMed
10.
Zurück zum Zitat Hohenfellner M, Black P, Linn JF, Dahms SE, Thüroff JW (2000) Surgical treatment of interstitial cystitis in women. Int Urogynecol J 11: 113CrossRef Hohenfellner M, Black P, Linn JF, Dahms SE, Thüroff JW (2000) Surgical treatment of interstitial cystitis in women. Int Urogynecol J 11: 113CrossRef
11.
Zurück zum Zitat Kirschner J, Berweck S, Mall V, Korinthenberg R, Heinen F (2001) Botulinum toxin treatment in cerebral palsy: evidence for a new treatment option. J Neurol 248 [Suppl 1: 28 Kirschner J, Berweck S, Mall V, Korinthenberg R, Heinen F (2001) Botulinum toxin treatment in cerebral palsy: evidence for a new treatment option. J Neurol 248 [Suppl 1: 28
12.
13.
Zurück zum Zitat Pannek J, Sommerfeld HJ, Bötel U, Senge T (2000) Combined intravesical and oral oxybutynin chloride in adult patients with spinal cord injury. Urology 55: 358CrossRefPubMed Pannek J, Sommerfeld HJ, Bötel U, Senge T (2000) Combined intravesical and oral oxybutynin chloride in adult patients with spinal cord injury. Urology 55: 358CrossRefPubMed
14.
Zurück zum Zitat Phelan MW, Franks M, Somogyi GT, Yokoyama T, Fraser MO, Lavelle JP, Yoshimura N, Chancellor MB (2001) Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J Urol 165: 1107PubMed Phelan MW, Franks M, Somogyi GT, Yokoyama T, Fraser MO, Lavelle JP, Yoshimura N, Chancellor MB (2001) Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J Urol 165: 1107PubMed
15.
Zurück zum Zitat Piechota HJ, Gleason CA, Dahms SE, Dahiya R, Nunes LS, Lue TF, Tanagho EA (1999) Bladder acellular matrix graft: in vivo functional properties of the regenerated rat bladder. Urol Res 27: 206CrossRefPubMed Piechota HJ, Gleason CA, Dahms SE, Dahiya R, Nunes LS, Lue TF, Tanagho EA (1999) Bladder acellular matrix graft: in vivo functional properties of the regenerated rat bladder. Urol Res 27: 206CrossRefPubMed
16.
Zurück zum Zitat Ratliff TL, Klutke CG, McDougall MM (1994) The etiology of interstitial cystitis. Urol Clin North Am 21: 21PubMed Ratliff TL, Klutke CG, McDougall MM (1994) The etiology of interstitial cystitis. Urol Clin North Am 21: 21PubMed
17.
Zurück zum Zitat Rivas DA, Chancellor MB, Shupp-Byrne D, Shenot PJ, McHugh K, McCue P (1997) A molecular marker for the development of interstitial cystitis in a rat model: isoactin gene expression. J Urol 157: 1937PubMed Rivas DA, Chancellor MB, Shupp-Byrne D, Shenot PJ, McHugh K, McCue P (1997) A molecular marker for the development of interstitial cystitis in a rat model: isoactin gene expression. J Urol 157: 1937PubMed
18.
Zurück zum Zitat Saadia D, Voustianiouk A, Wang AK, Kaufmann H (2001) Botulinum toxin type A in primary palmar hyperhidrosis: randomized, single-blind, two-dose study. Neurology 57: 2095PubMed Saadia D, Voustianiouk A, Wang AK, Kaufmann H (2001) Botulinum toxin type A in primary palmar hyperhidrosis: randomized, single-blind, two-dose study. Neurology 57: 2095PubMed
19.
Zurück zum Zitat Sant GR, Theoharides TC (1994) The role of the mast cell in interstitial cystitis. Urol Clin North Am 21: 41PubMed Sant GR, Theoharides TC (1994) The role of the mast cell in interstitial cystitis. Urol Clin North Am 21: 41PubMed
20.
Zurück zum Zitat Schurch B, Stöhrer M, Kramer G, Schmid DM, Gaul G, Hauri D (2000) Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: A new alternative to anticholinergic drugs? Preliminary results. J Urol 164: 692PubMed Schurch B, Stöhrer M, Kramer G, Schmid DM, Gaul G, Hauri D (2000) Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: A new alternative to anticholinergic drugs? Preliminary results. J Urol 164: 692PubMed
21.
Zurück zum Zitat Schurch B, Schmid DM, Stohrer M (2001) Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med 342: 665CrossRef Schurch B, Schmid DM, Stohrer M (2001) Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med 342: 665CrossRef
22.
Zurück zum Zitat Schwantes U, Topfmeier P (1999) Importance of pharmacological and physicochemical properties for tolerance of antimuscarinic drugs in the treatment of detrusor instability and detrusor hyperreflexia—chances for improvement of therapy. Int J Clin Pharmacol Ther 37: 209PubMed Schwantes U, Topfmeier P (1999) Importance of pharmacological and physicochemical properties for tolerance of antimuscarinic drugs in the treatment of detrusor instability and detrusor hyperreflexia—chances for improvement of therapy. Int J Clin Pharmacol Ther 37: 209PubMed
23.
Zurück zum Zitat Shekarriz B, Upadhyay J, Demirbilek S, Barthold JS, Gonzalez R (2000) Surgical complications of bladder augmentation: comparison between various enterocystoplasties in 133 patients. Urology 55: 123CrossRefPubMed Shekarriz B, Upadhyay J, Demirbilek S, Barthold JS, Gonzalez R (2000) Surgical complications of bladder augmentation: comparison between various enterocystoplasties in 133 patients. Urology 55: 123CrossRefPubMed
24.
Zurück zum Zitat Simpson LL (1981) The origin, stricture, and pharmacological activity of botulinum toxin. Pharmacol Rev 33: 155PubMed Simpson LL (1981) The origin, stricture, and pharmacological activity of botulinum toxin. Pharmacol Rev 33: 155PubMed
25.
Zurück zum Zitat Theoharides TC, Pang X, Letourneau R, Sant GR (1998) Interstitial cystitis: a neuroimmunoendocrine disorder. Ann N Y Acad Sci 840: 619PubMed Theoharides TC, Pang X, Letourneau R, Sant GR (1998) Interstitial cystitis: a neuroimmunoendocrine disorder. Ann N Y Acad Sci 840: 619PubMed
26.
Zurück zum Zitat Zermann DH, Ishigooka M, Schubert J, Schmidt RA (2000) Perisphincteric injection of Botulinum toxin type A: a treatment option for patients with chronic prostatic pain. Eur Urol 38: 393CrossRefPubMed Zermann DH, Ishigooka M, Schubert J, Schmidt RA (2000) Perisphincteric injection of Botulinum toxin type A: a treatment option for patients with chronic prostatic pain. Eur Urol 38: 393CrossRefPubMed
Metadaten
Titel
Botulinum toxin type A may improve bladder function in a rat chemical cystitis model
verfasst von
Selahittin Çayan
Banu Coşkun
Murat Bozlu
Deniz Acar
Erdem Akbay
Ercüment Ulusoy
Publikationsdatum
01.02.2003
Verlag
Springer-Verlag
Erschienen in
Urolithiasis / Ausgabe 6/2003
Print ISSN: 2194-7228
Elektronische ISSN: 2194-7236
DOI
https://doi.org/10.1007/s00240-002-0291-0

Weitere Artikel der Ausgabe 6/2003

Urolithiasis 6/2003 Zur Ausgabe

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Männern mit Zystitis Schmalband-Antibiotika verordnen

03.05.2024 Zystitis Nachrichten

Die akute Zystitis von Männern und ihre Therapie sind wenig erforscht. Norwegische Forscher haben das nachgeholt. Ihr Rat: Erst einmal keine Breitbandantibiotika verordnen.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.